15 July 2021 - Ocugen today announced that it had initiated a rolling submission to Health Canada for Covaxin, the company’s candidate vaccine against COVID-19, which it is co-developing with Bharat Biotech for the U.S. and Canadian markets.

The rolling submission process was recommended and accepted under the Minister of Health’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 and transitioned to a New Drug Submission for COVID-19, which permits companies to submit safety and efficacy data and information as they become available.

Read Ocugen press release